Vanguard Group Inc. Has $52.45 Million Stock Position in Nurix Therapeutics, Inc. $NRIX

Key Points

• Vanguard Group Inc. increased its stake in Nurix Therapeutics by 1.6%, acquiring an additional 69,856 shares, bringing its total holdings to 4,415,122 shares valued at approximately $52.45 million.
• Several hedge funds have also increased their positions in Nurix Therapeutics, with notable acquisitions from RA Capital Management and Soleus Capital Management during the previous quarter.
• The stock currently has a consensus rating of "Moderate Buy" among analysts, with a consensus target price of $28.87, despite recent adjustments showing price targets ranging from $16.00 to $34.00.

Vanguard Group Inc. grew its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 1.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,415,122 shares of the company's stock after purchasing an additional 69,856 shares during the period. Vanguard Group Inc. owned about 5.79% of Nurix Therapeutics worth $52,452,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. The Manufacturers Life Insurance Company lifted its stake in Nurix Therapeutics by 2.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company's stock worth $585,000 after acquiring an additional 642 shares in the last quarter. Arizona State Retirement System lifted its stake in Nurix Therapeutics by 8.7% in the 1st quarter. Arizona State Retirement System now owns 17,253 shares of the company's stock worth $205,000 after acquiring an additional 1,385 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Nurix Therapeutics in the 4th quarter worth about $28,000. Woodline Partners LP lifted its stake in Nurix Therapeutics by 0.5% in the 4th quarter. Woodline Partners LP now owns 338,462 shares of the company's stock worth $6,377,000 after acquiring an additional 1,583 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Nurix Therapeutics by 13.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,829 shares of the company's stock worth $224,000 after acquiring an additional 2,260 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on NRIX. Oppenheimer reissued an "outperform" rating and issued a $30.00 price objective (down from $32.00) on shares of Nurix Therapeutics in a research note on Thursday, July 31st. Stephens reaffirmed an "overweight" rating and issued a $30.00 target price on shares of Nurix Therapeutics in a research report on Thursday, July 10th. Baird R W raised Nurix Therapeutics to a "strong-buy" rating in a research report on Tuesday, August 26th. UBS Group dropped their target price on Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, July 10th. Finally, Wall Street Zen raised Nurix Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Nurix Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $28.87.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX traded down $0.07 during mid-day trading on Friday, reaching $9.34. 1,832,002 shares of the company traded hands, compared to its average volume of 675,848. The stock has a market cap of $714.04 million, a PE ratio of -3.58 and a beta of 2.10. The company's fifty day moving average is $11.20 and its two-hundred day moving average is $11.73. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. The business had revenue of $44.06 million for the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. Research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,402 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $11.03, for a total value of $59,584.06. Following the sale, the chief financial officer owned 35,512 shares of the company's stock, valued at $391,697.36. This trade represents a 13.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 4,308 shares of the firm's stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total value of $51,739.08. Following the completion of the sale, the insider directly owned 69,023 shares in the company, valued at $828,966.23. This trade represents a 5.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,014 shares of company stock worth $163,014 in the last ninety days. Insiders own 7.40% of the company's stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.